(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 13 Publications

9 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    Int J Stem Cells, 2018, 11(1):131-140. (+)-JQ1 purchased from Selleck.

  • JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

    immunofluorescence staining of BRD4 in ACC-LM and ACC-83 cells treated with JQ1 at the concentration of 1 µM for 24 h (×200).

    Biol Res, 2017, 50(1):19. (+)-JQ1 purchased from Selleck.

  • Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  MkX4R4VtdCCYaXHibYxqfHliQYPzZZk> M4rTWVI2OC93MECvNVAxOCCwTR?= MWqyOE81QC95MjDo MXjEUXNQ NWTLNnY{cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? NXj5NGxCOjZ5MEe4PFE>
BCPAP MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mmn5NlUxNzVyMD:xNFAxKG6P MVSyOE81QC95MjDo M{m5e2ROW09? NE\EfHhqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz M2XkdVI3PzB5OEix
K1  MVrD[YxtKEO7Y3zlJGF{e2G7 NHXjWWczPTBxNUCwM|ExODBibl2= NW\sUVFSPzJiaB?= NI[1VIxFVVOR NHf0ZYlienKnc4TzJINmdGxiY4njcIUh[XRiR{CvS|EheGijc3W= NWrBb4ZnOjZ5MEe4PFE>
BCPAP MnuxR4VtdCCFeXPs[UBCe3OjeR?= MkTINlUxNzVyMD:xNFAxKG6P MYe3NkBp NF;0TW5FVVOR NIHH[49ienKnc4TzJINmdGxiY4njcIUh[XRiR{CvS|EheGijc3W= NGPHbWQzPjdyN{i4NS=>
Hep3B MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jjXVAuOTBizszN M2PpXFUh\A>? NVvqWnU5TE2VTx?= NHzjeWNKSzVyPUCuNFgh|ryP MlL6NlY2PzVzNke=
HCCLM3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i4WFAuOTBizszN MlzHOUBl NVnNVoRmTE2VTx?= MUfJR|UxRTBwMUSg{txO NEewO24zPjV5NUG2Oy=>
HuH7 NXflTHRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjDRXIxNTFyIN88US=> MknNOUBl MYTEUXNQ M4DFV2lEPTB;MD6yNUDPxE1? MWGyOlU4PTF4Nx?=
HepG2 M2XBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTkNE0yOCEQvF2= M2jDdVUh\A>? M2qyUWROW09? MWXJR|UxRTBwM{Sg{txO MkToNlY2PzVzNke=
SMMC7721 NGDSZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYmwMVExKM7:TR?= MYq1JIQ> M1;HTGROW09? M{GzOmlEPTB;MD60NUDPxE1? NGP2TWYzPjV5NUG2Oy=>
BEL7402 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYWwMVExKM7:TR?= MWq1JIQ> NX7sPXdCTE2VTx?= MnfNTWM2OD1yLkS3JO69VQ>? NH[yT2czPjV5NUG2Oy=>
MHCC97H NX3yfIxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzQNE0yOCEQvF2= NY[1WWR1PSCm NEfie5lFVVOR M2fLemlEPTB;MD60NUDPxE1? MkLRNlY2PzVzNke=
Hep3B MXXD[YxtKEO7Y3zlJGF{e2G7 MYewMlEwOC53L{KuOUDPxE1? M1XFOVQ5KGh? NFzBcYlFVVOR NHTM[2tt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iCKQ1OgZ4VtdHNiaX6gd5VjNUdzIIDoZZNmyqB? NGjPZmszPjV5NUG2Oy=>
HCCLM3 NX\obZVrS2WubDDDfYNt\SCDc4PhfS=> NFv6bIYxNjFxMD61M|IvPSEQvF2= M3TCflQ5KGh? MmLlSG1UVw>? MXns[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA> MkTvNlY2PzVzNke=
Hep3B MnXURZBweHSxc3nzJGF{e2G7 MYqwMlEwOC53L{KuOUDPxE1? NH\Gd4Q1QCCq M1jFSmROW09? MYDhZ5RqfmG2ZYOgZ4F{eGG|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli NH;4eGszPjV5NUG2Oy=>
HCCLM3 MX\BdI9xfG:|aYOgRZN{[Xl? MUmwMlEwOC53L{KuOUDPxE1? MWi0PEBp M4HTcmROW09? NYHn[3Rk[WO2aY\heIV{KGOjc4Dhd4UuOyCjbnSgZ4F{eGG|ZT25JIV5eHKnc4Ppc44h[W6mIHnu[JVk\WRiUFHSVEBkdGWjdnHn[UBieyC5ZXzsJIF{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bTDmdo9uKG2rdH;jbI9v\HKrYR?= NUPOb5dNOjZ3N{WxOlc>
A549 NF;aNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUiwMlEuOTBizszN M3Xr[FczKGh? M3Xm[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NV3Ee4Z{OjZ2MUWyNlU>
H157 NX36dItrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HMeFAvOS1zMDFOwG0> MUi3NkBp MmPFbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NH74R2UzPjRzNUKyOS=>
H1299 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf2VHQxNjFvMUCg{txO M1zNcFczKGh? M1PvdYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYKyOlQyPTJ{NR?=
A549 MYnGeY5kfGmxbjDBd5NigQ>? NICxXHAyNzJwNT:1JO69VQ>? NUGzU5lwOTJiaB?= MXJCpJdm[WuueTDk[YNz\WG|ZXSgRoNtNTJibHX2[Yx{ NU\kUolzOjZ2MUWyNlU>
H1299 M2Drd2Z2dmO2aX;uJGF{e2G7 MXuxM|IvPS93IN88US=> MmTvNVIhcA>? MmX6xsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>? NVy1e2VKOjZ2MUWyNlU>
H157 Ml24SpVv[3Srb36gRZN{[Xl? NXXBenI3OS9{LkWvOUDPxE1? MUGxNkBp M1fON4Rm[3KnYYPl[EBFWjRiZYjwdoV{e2mxbh?= MYiyOlQyPTJ{NR?=
H1299 NUHKcoJYTnWwY4Tpc44hSXO|YYm= M{nJU|EwOi53L{Wg{txO NYnCO41lOTJiaB?= NYTWTFdu\GWlcnXhd4VlKESUNDDlfJBz\XO|aX;u MkjQNlY1OTV{MkW=
C8161 M4rtOmNmdGxiVnnhZoltcXS7IFHzd4F6 M1jK[VAuOiEQvF2= MlvyOEBl MVrEUXNQ MYTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWT6dnhYOjZ|OUeyNlM>
Mel285 M{fGfWNmdGxiVnnhZoltcXS7IFHzd4F6 NXfTOWhnOC1{IN88US=> MUm0JIQ> M3XGemROW09? Mmf6[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYiyOlM6PzJ{Mx?=
Mel290 MWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkizNE0zKM7:TR?= MWC0JIQ> M{LmfGROW09? MlPV[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWiyOlM6PzJ{Mx?=
92.1 MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NV7TNllGOC1{IN88US=> M{e1cVQh\A>? NF3meGlFVVOR M2HGPYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoHaNlY{QTd{MkO=
Omm1.3 MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUTUcpJNOC1{IN88US=> NXTMVlVqPCCm M{LkPWROW09? M3e3eYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYiyOlM6PzJ{Mx?=
Mel202 NVexXmk{S2WubDDWbYFjcWyrdImgRZN{[Xl? MnfVNE0zKM7:TR?= MVm0JIQ> M2jLTmROW09? MlK3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVyyOlM6PzJ{Mx?=
Mel270 NYn4THN3S2WubDDWbYFjcWyrdImgRZN{[Xl? Mny2NE0zKM7:TR?= NHG3ToM1KGR? MlvMSG1UVw>? Morz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MUOyOlM6PzJ{Mx?=
Omm1 NXjrOFBIS2WubDDWbYFjcWyrdImgRZN{[Xl? NUj5WFJiOC1{IN88US=> NUfnTZF5PCCm MoX6SG1UVw>? M{fT[4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoXlNlY{QTd{MkO=
92.1 NIfoNFVCeG:ydH;zbZMhSXO|YYm= NYWxZlE5PTByIH7N NIjmZ5A1QCCq MmnMSG1UVw>? MWfpcoR2[2W|IHHwc5B1d3Orcx?= NVrKb4hEOjZ|OUeyNlM>
Omm1.3 NUXKWW9TSXCxcITvd4l{KEG|c3H5 NUS4cphtPTByIH7N NEHScVQ1QCCq MoCxSG1UVw>? NXfUSY5pcW6mdXPld{BieG:ydH;zbZM> M1jIWFI3Ozl5MkKz
92.1 NHT6W4JE\WyuIFP5Z4xmKEG|c3H5 MkfFOVAxKG6P Mm[1NlQwPDhxN{KgbC=> MV7EUXNQ Moi0bY5lfWOnczD0bIUh[2WubDDhZ4N2dXWuYYTpc44h[XRic4XiMWcyyqB? M1;2dVI3Ozl5MkKz
Omm1.3 NGPENnNE\WyuIFP5Z4xmKEG|c3H5 MVe1NFAhdk1? M4fCTlI1NzR6L{eyJIg> Mkm1SG1UVw>? M2joN4lv\HWlZYOgeIhmKGOnbHygZYNkfW23bHH0bY9vKGG2IIP1Zk1IOcLi NHiwV|QzPjN7N{KyNy=>
A549 MVfGeY5kfGmxbjDBd5NigQ>? MYKxNFAwPDByL{GwNFAhdk1? NUPBTIxqOjRiaB?= NVK0PJg4fXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= MlPHNlYzOTJzOUm=
MCF-7 NXuyPXVwTnWwY4Tpc44hSXO|YYm= NUXLRm9oOTByL{SwNE8yODByIH7N MX2yOEBp NGLnV4x2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz M3HRN|I3OjF{MUm5
HEK293 MYrGeY5kfGmxbjDBd5NigQ>? MlvyNVAxNzRyMD:xNFAxKG6P NHO4V2kzPCCq NHeyRYx2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz Mmq4NlYzOTJzOUm=
858 M4PHdmNmdGxiVnnhZoltcXS7IFHzd4F6 MkCxNE0yKM7:TR?= NVToZmlSPSCm NXvMXFVOTE2VTx?= Mn\T[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NY\VbHc4OjZ{ME[zN|M>
DDR2L63V MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIrqeHgxNTFizszN NF3TWlU2KGR? MlLQSG1UVw>? MoPx[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3y0NlI3OjB4M{Oz
BE(2)-C MmHwR4VtdCCYaXHibYxqfHliQYPzZZk> NEjuSYEyKM7:TR?= NFT6RlIyNTRiZB?= MnL2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MWiyOlA3PzR4NB?=
IMR-32 MmW1R4VtdCCYaXHibYxqfHliQYPzZZk> MkTKNUDPxE1? M3zYeVEuPCCm M2PnZoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MUiyOlA3PzR4NB?=
JF NWrTZ4hkS2WubDDWbYFjcWyrdImgRZN{[Xl? M4\m[VEh|ryP MX:xMVQh\A>? NGDnSnZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? M3HTW|I3ODZ5NE[0
BE(2)-M17 NUHRSopPS2WubDDWbYFjcWyrdImgRZN{[Xl? MUixJO69VQ>? MlPnNU01KGR? NEXnXWJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? M{\VUVI3ODZ5NE[0
SK-N-SH MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3Pxc|Eh|ryP MlTaNU01KGR? Ml:1[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NX;Sfox6OjZyNke0OlQ>
SK-N-DZ  MlrYR4VtdCCYaXHibYxqfHliQYPzZZk> MWmxJO69VQ>? NXzmRVVGOS12IHS= M4\NeIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 M1XMNFI3ODZ5NE[0
HMC-1.1  MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn70OU02ODByIH7N Mom4OFghcA>? MVnEUXNQ MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXWyOlA2PTNyMx?=
HMC-1.2 NYrsVIo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG5OU02ODByIH7N NWD2SWpIPDhiaB?= NXrxRnBlTE2VTx?= NFrvWo1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{jETFI3ODV3M{Cz
ROSA KIT WT  NXzsOlEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVy1MVUxODBibl2= NV7pXYR[PDhiaB?= NI\p[GxFVVOR NIqybmhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NGLSbGMzPjB3NUOwNy=>
ROSA KIT D816V NHjtR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfROU02ODByIH7N M4PlPVQ5KGh? M4DtVWROW09? M1rFN4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVyyOlA2PTNyMx?=
HMC-1.1  NVX0doZJSXCxcITvd4l{KEG|c3H5 NFHPWJYzODBvNUCwNEBvVQ>? NFzJelc1QCCq MWDEUXNQ NYnQNnhocW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MknjNlYxPTV|MEO=
HMC-1.2 MWnBdI9xfG:|aYOgRZN{[Xl? NWj2T|ZrOjByLUWwNFAhdk1? MVm0PEBp NEXSV2lFVVOR MWLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnHwNlYxPTV|MEO=
ROSA KIT WT  M1vDWmFxd3C2b4Ppd{BCe3OjeR?= MVeyNFAuPTByMDDuUS=> M{jDfVQ5KGh? MYnEUXNQ MXzpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4W4OVI3ODV3M{Cz
ROSA KIT D816V M3\tW2Fxd3C2b4Ppd{BCe3OjeR?= MoWxNlAxNTVyMECgcm0> NYrGTGttPDhiaB?= MWLEUXNQ MkDybY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4fFNVI3ODV3M{Cz
494H M1TTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL0U4RGPzJiaB?= M3O5bWROW09? NVjr[5BQUUN3ME2wMlEzOsLzMD6wNFQh|ryP MlnMNlU6PDR3Nk[=
493H M3qyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy3NkBp NHzTe4tFVVOR MUXJR|UxRTBwMES3xtExNjByOTFOwG0> MX2yOVk1PDV4Nh?=
716H NWrWZ3ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7C[Ho4OiCq NI\OPZdFVVOR M1jGVmlEPTB;MD6yNVLDuTBwMEO0JO69VQ>? MV[yOVk1PDV4Nh?=
148I MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7obG84OiCq MV3EUXNQ M2PMRWlEPTB;MD6yPFTDuTBwMEO1JO69VQ>? NFfYdlgzPTl2NEW2Oi=>
98Sc M2XMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED5dos4OiCq MXHEUXNQ M2exdGlEPTB;MD6xNVXDuTBwMEC0JO69VQ>? M4DKUVI2QTR2NU[2
89R MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjMd|h5PzJiaB?= NY\FU25oTE2VTx?= MVPJR|UxRTBwMUK2xtExNjByMzFOwG0> M{DpUlI2QTR2NU[2
494L NFT3PJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzWO|IhcA>? MlXjSG1UVw>? MkP3TWM2OD1yLkOxO:KyOC5yMUKg{txO MUCyOVk1PDV4Nh?=
493L NILxSmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn36O|IhcA>? NFfzV5hFVVOR NF\kWYJKSzVyPUCuNFUxyrFyLkCxNUDPxE1? NIe1dm8zPTl2NEW2Oi=>
148L M2nJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7EOpc4OiCq MnTOSG1UVw>? NIDlN5VKSzVyPUCuNVQ3yrFyLkCxO{DPxE1? MWeyOVk1PDV4Nh?=
98L MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfaUot1PzJiaB?= NXzteHk6TE2VTx?= MoLITWM2OD1yLkOwPeKyOC5yMkmg{txO M3XERVI2QTR2NU[2
OS17 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHLO|IhcA>? Mlu3SG1UVw>? M3SwfmlEPTB;MD6wO|nDuTBwMECzJO69VQ>? Mn31NlU6PDR3Nk[=
OS9 M2jGS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[4O|IhcA>? Ml\tSG1UVw>? M4\rPWlEPTB;MD60NFbDuTBwMEK4JO69VQ>? NEHGTVIzPTl2NEW2Oi=>
MG63 Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPxO|IhcA>? M4fFOGROW09? MVjJR|UxRTBwMUG0xtExNjB{NTFOwG0> MnvyNlU6PDR3Nk[=
SAOS2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfUO|IhcA>? MWnEUXNQ NWjDTnJDUUN3ME2wMlIyP8LzMD6wNFMh|ryP NHfKbY0zPTl2NEW2Oi=>
U2OS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXMfHg4OiCq MWfEUXNQ M4H5[GlEPTB;MD6xPVjDuTBwMEC4JO69VQ>? NHrtPIozPTl2NEW2Oi=>
SJSA-1 NV7ke2s5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTvO|IhcA>? M37lfGROW09? MUPJR|UxRTBwMUCwxtExNjBzMDFOwG0> M1fnblI2QTR2NU[2
494H MV7BdI9xfG:|aYOgRZN{[Xl? NUXuNVMzOC5{NT:wMlUwOS5yIN88US=> NFv6cHgzPCCq MYXEUXNQ MX;pcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> MkK4NlU6PDR3Nk[=
148I NXr5dJZYSXCxcITvd4l{KEG|c3H5 NIfZcXYxNjJ3L{CuOU8yNjBizszN M3rPO|I1KGh? M2Pid2ROW09? NGKyU29qdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G|cHHz[U0{yqB? NWH6ZVczOjV7NES1OlY>
OS17 M4e3dWFxd3C2b4Ppd{BCe3OjeR?= MWCwMlI2NzBwNT:xMlAh|ryP NVLzW5dbOjRiaB?= NE\3NINFVVOR MYDpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> NVTYdZh5OjV7NES1OlY>
494H M1TUNGFxd3C2b4Ppd{BCe3OjeR?= M{PieVHjiIoQvF2= M3LEd|Q5KGh? NInOVGVFVVOR MkPhbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 MlvnNlU6PDR3Nk[=
148I MVjBdI9xfG:|aYOgRZN{[Xl? NHLDSoQy6oDLzszN NI\SfGs1QCCq NFXaW5RFVVOR MV\pcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= NX7Zb2dOOjV7NES1OlY>
OS17 NWHob5pQSXCxcITvd4l{KEG|c3H5 M4TPN|HjiIoQvF2= M4TNWlQ5KGh? MYTEUXNQ MUnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= MmC3NlU6PDR3Nk[=
MOLM13 MWHBdI9xfG:|aYOgRZN{[Xl? NEDDNpIzPTBibl2= Mn:0OFghcA>? MUXEUXNQ MluwbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHG3aYrhdpRqdmmk MVuyOVA2Ozh{NR?=
MV4-11  MXHBdI9xfG:|aYOgRZN{[Xl? M2\vUVI2OCCwTR?= NVvmenlHPDhiaB?= NEPi[JpFVVOR NWrU[WZVcW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIH1bZpienSrbnni MUGyOVA2Ozh{NR?=
MOLM13 MlHYSpVv[3Srb36gRZN{[Xl? M3XoelI2OCCwTR?= MVeyOEBp M2fvdGROW09? M1nTVYVvcGGwY3XzJJF2cXqjcoTpcoljNWmwZIXj[YQhdW:{ZTDwNlEtKEKLTTygZY5lKGOuZXH2[YQhWEGUUB?= MoL2NlUxPTN6MkW=
MV4-11  MUPGeY5kfGmxbjDBd5NigQ>? M3fMNlI2OCCwTR?= NUXGVnpiOjRiaB?= NETzZ2ZFVVOR M1v3OIVvcGGwY3XzJJF2cXqjcoTpcoljNWmwZIXj[YQhdW:{ZTDwNlEtKEKLTTygZY5lKGOuZXH2[YQhWEGUUB?= NYTlT3pQOjVyNUO4NlU>
MOLM13 M3HMSmFxd3C2b4Ppd{BCe3OjeR?= NE\YUFUzPTBibl2= M2j3RVQ5KGh? M4qwfGROW09? NXXxOWRIcW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIDvcoF1cW6rYh?= MW[yOVA2Ozh{NR?=
MV4-11  NV\PdooySXCxcITvd4l{KEG|c3H5 M4rF[FI2OCCwTR?= NWTHN5RyPDhiaB?= M1vp[WROW09? NHrBbYNqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk NHnLSGszPTB3M{iyOS=>
Hela M3r1S2NmdGxiVnnhZoltcXS7IFHzd4F6 M2j2TVAuPTByIH7N MnvDO|IhcA>? M{Wwd2ROW09? Mn25[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnK3NlUxODl{OUW=
HBL-1 M2H2eWNmdGxiVnnhZoltcXS7IFHzd4F6 MojyNE02ODBibl2= NX3LOo1oPzJiaB?= MkTSSG1UVw>? NWrJUWJI\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWr1fVNLOjVyMEmyPVU>
HLY-1 NXPUVJhZS2WubDDWbYFjcWyrdImgRZN{[Xl? M{nGclAuPTByIH7N Ml7RO|IhcA>? M4XVfWROW09? MXLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXiyOVAxQTJ7NR?=
OCI-Ly3 M3XSWmNmdGxiVnnhZoltcXS7IFHzd4F6 NITVVIQxNTVyMDDuUS=> M2LrWVczKGh? MmTISG1UVw>? MkjZ[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYOyOVAxQTJ7NR?=
OCI-Ly10 Mk\FR4VtdCCYaXHibYxqfHliQYPzZZk> NEDuVYkxNTVyMDDuUS=> M1jxc|czKGh? NWCyZoZWTE2VTx?= MlLx[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NHq5PVEzPTByOUK5OS=>
SU-DHL-4 Mn3sR4VtdCCYaXHibYxqfHliQYPzZZk> M{fjcVAuPTByIH7N MlTXO|IhcA>? NVHFe2Q4TE2VTx?= MWHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2XtdFI2ODB7Mkm1
SU-DHL-5 MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUfYRYxmOC13MECgcm0> Mon2O|IhcA>? M2rjSGROW09? M{XPToRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MleyNlUxODl{OUW=
SU-DHL-6 MnfxR4VtdCCYaXHibYxqfHliQYPzZZk> M13lVlAuPTByIH7N NWHyUW96PzJiaB?= MnjpSG1UVw>? M3Tuc4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3z3UFI2ODB7Mkm1
SU-DHL-10 NInxfG5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXmwMVUxOCCwTR?= MWC3NkBp MnTjSG1UVw>? MmfX[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NY\E[phUOjVyMEmyPVU>
RC-K8 NGr1V41E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWT4dY1oOC13MECgcm0> Mlz0O|IhcA>? NFrPRWlFVVOR MVzk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mnz5NlUxODl{OUW=
OCI-Ly8 MoLLR4VtdCCYaXHibYxqfHliQYPzZZk> MmDjNE02ODBibl2= MXW3NkBp M1X3XmROW09? Mom4[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MXiyOVAxQTJ7NR?=
OCL-Ly18 MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlLENE02ODBibl2= NWiyN2w3PzJiaB?= NXrOb4VkTE2VTx?= M1\Yb4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2DkNVI2ODB7Mkm1
OCI-Ly3 NWjGV4N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHZXJIyPzJxMkWwM|UxOCCwTR?= M33CTFIwPyCm NWnScWJjTE2VTx?= NV7hUG9LcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> MmHmNlUxODl{OUW=
OCI-Ly8 NGnQUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHJe2oyPzJxMkWwM|UxOCCwTR?= NV;XWG5wOi95IHS= NXGzR3pITE2VTx?= NU[zXG5lcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> NVzQUIo6OjVyMEmyPVU>
SU-DHL-4 MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXDNVczNzJ3MD:1NFAhdk1? NWDn[3lFOi95IHS= M4q1fGROW09? M1nZVYlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= NHnaeWgzPTByOUK5OS=>
SU-DHL-10 MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHP[GlYOTd{L{K1NE82ODBibl2= MmfpNk84KGR? Mkf1SG1UVw>? MkexbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= MWSyOVAxQTJ7NR?=
OCI-Ly3 MmHDRZBweHSxc3nzJGF{e2G7 MkDRNVczNzJ3MDDuUS=> M1jpfFdl MXHEUXNQ MWfpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= NV\SZnRFOjVyMEmyPVU>
OCI-Ly8 Ml7PRZBweHSxc3nzJGF{e2G7 M1THbVE4Oi9{NUCgcm0> NYjNNJJLP2R? NX3vNld3TE2VTx?= NXPiXnVrcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 NUf4VZNmOjVyMEmyPVU>
SU-DHL-4 NE\ZWXBCeG:ydH;zbZMhSXO|YYm= MmPENVczNzJ3MDDuUS=> NV;BZXo3P2R? NWTRNpgyTE2VTx?= MXLpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= MXSyOVAxQTJ7NR?=
SU-DHL-10 MV;BdI9xfG:|aYOgRZN{[Xl? NU\YZ25zOTd{L{K1NEBvVQ>? MUC3[C=> M3;WXWROW09? NVrHS4hxcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 NYTCZZp7OjVyMEmyPVU>

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID